- Home
- CMPR vs COLL Comparison
CMPR vs COLL Comparison
Compare CMPR & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPR
- COLL
- Stock Information
- Founded
- CMPR 1994
- COLL 2002
- Country
- CMPR Ireland
- COLL United States
- Employees
- CMPR N/A
- COLL N/A
- Industry
- CMPR Publishing
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- CMPR Consumer Discretionary
- COLL Health Care
- Exchange
- CMPR Nasdaq
- COLL Nasdaq
- Market Cap
- CMPR 1.2B
- COLL 958.8M
- IPO Year
- CMPR N/A
- COLL 2015
- Fundamental
- Price
- CMPR $59.06
- COLL $37.74
- Analyst Decision
- CMPR Strong Buy
- COLL Strong Buy
- Analyst Count
- CMPR 2
- COLL 4
- Target Price
- CMPR $72.00
- COLL $44.25
- AVG Volume (30 Days)
- CMPR 268.9K
- COLL 387.3K
- Earning Date
- CMPR 07-29-2025
- COLL 08-07-2025
- Dividend Yield
- CMPR N/A
- COLL N/A
- EPS Growth
- CMPR N/A
- COLL N/A
- EPS
- CMPR 0.58
- COLL 1.06
- Revenue
- CMPR $3,403,079,000.00
- COLL $707,007,000.00
- Revenue This Year
- CMPR $4.43
- COLL $20.47
- Revenue Next Year
- CMPR $3.29
- COLL $2.91
- P/E Ratio
- CMPR $101.83
- COLL $35.64
- Revenue Growth
- CMPR 3.38
- COLL 22.61
- 52 Week Low
- CMPR $35.21
- COLL $23.23
- 52 Week High
- CMPR $102.22
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- CMPR 68.87
- COLL 71.52
- Support Level
- CMPR $54.34
- COLL $36.62
- Resistance Level
- CMPR $61.23
- COLL $38.24
- Average True Range (ATR)
- CMPR 2.66
- COLL 1.24
- MACD
- CMPR 0.55
- COLL 0.69
- Stochastic Oscillator
- CMPR 82.94
- COLL 94.53
About CMPR Cimpress plc (Ireland)
Cimpress PLC invests in and builds customer-focused, entrepreneurial, mass-customization businesses for the long term. Mass customization seeks to produce goods and services to meet individual customer needs with near mass production efficiency. Its products and services include a broad range of marketing materials, business cards, signage, promotional products, logo apparel, packaging, books and magazines, wall decor, photo merchandise, invitations and announcements, design and digital marketing services, and other categories. The company's segment includes Vista; PrintBrothers; The Print Group; National Pen and All Other Businesses. It generates maximum revenue from the Vista segment.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.